Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26244
Title: Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials
Authors: Wijns, William
VROLIX, Mathias 
Verheye, Stefan
Schoors, Danny
Slagboom, Ton
Gosselink, Marcel
BENIT, Edouard 
Kandzari, David
Donohoe, Dennis
Ormiston, John
Issue Date: 2018
Source: EUROINTERVENTION, 13(18), p. E2147-E2151
Abstract: Aims: The aim of this study was to evaluate the five-year clinical results of a sirolimus-eluting stent (MiStent SES) with a bioabsorbable coating designed for sustained drug delivery during and after rapid polymer dissolution. Methods and results: The five-year results from the DESSOLVE I and II trials including major adverse cardiac events (MACE), target lesion failure (TLF), target vessel failure (TVF), and stent thrombosis (ST) at five-year follow-up are reported. In DESSOLVE I, 10.3% of patients receiving the MiStent SES (3/29) had a MACE event up to five years without TLF. In DESSOLVE II, 15.1% of patients in the MiStent group (18/119) had a five-year MACE event compared to 22.0% of patients in the Endeavor group (p= 0.295). TLF was 9.2% in the MiStent group and 8.5% in the Endeavor group (p= 1.00). TVF was 10.1% for MiStent versus 15.3% for Endeavor (p= 0.331). Up to five-year follow-up, the MiStent SES has continued to demonstrate low rates of TLR across DESSOLVE I (0.0%) and DESSOLVE II (3.4%). No ST was reported with the MiStent up to five years in the DESSOLVE I trial. In DESSOLVE II, definite or probable ST was 0.0% with MiStent and 1.7% with Endeavor up to five years. Conclusions: The MiStent SES demonstrated long-term safety and effectiveness with low rates of fiveyear MACE, TLF, and TVF across these two clinical trials.
Notes: Wijns, W (reprint author), Natl Univ Ireland Galway, Lambe Inst Translat Med, Floor 2,Univ Rd, Galway H91 TK33, Ireland. William.Wyns@nuigalway.ie
Keywords: clinical research; clinical trials; drug-eluting stent; multiple vessel disease; single vessel disease
Document URI: http://hdl.handle.net/1942/26244
ISSN: 1774-024X
e-ISSN: 1969-6213
DOI: 10.4244/EIJ-D-17-00230
ISI #: 000430649300013
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

SCOPUSTM   
Citations

4
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

9
checked on May 21, 2022

Page view(s)

66
checked on May 21, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.